سعر ميتوبروناد 5مجم/5مل 3 امبولات 2026

Metoprolol tartrate 5 mg/5 ml solution for intravenous injection (Metopronad, Inad Pharma); box of 3 ampoules.

• Definite or suspected acute myocardial infarction in haemodynamically stable patients, to reduce cardiovascular mortality, together with oral metoprolol maintenance.Population: AdultsDailyMed (U.S. NLM)

• Most common: tiredness, dizziness, shortness of breath, bradycardia, hypotension and pruritus.International label, same formulation · DailyMed (U.S. NLM)

• Hypersensitivity to metoprolol, related derivatives, excipients or other beta blockers.International label, same formulation · DailyMed (U.S. NLM)
• Heart rate <45 beats/min; second- or third-degree heart block without a functioning pacemaker; significant first-degree block (PR >=0.24 s); systolic BP <100 mmHg; decompensated cardiac failure.International label, same formulation · DailyMed (U.S. NLM)

• Bradycardia including sinus pause, heart block and cardiac arrest may occur; reduce or stop if severe.International label, same formulation · DailyMed (U.S. NLM)
• May worsen heart failure; bronchospastic disease generally should not receive beta blockers (keep bronchodilators available); in pheochromocytoma start an alpha blocker first; may mask hypoglycaemia; may aggravate peripheral arterial insufficiency.International label, same formulation · DailyMed (U.S. NLM)

• Catecholamine-depleting drugs (e.g. reserpine) and MAO inhibitorsAdditive effect; watch for hypotension or marked bradycardia.DailyMed (U.S. NLM)
• Strong CYP2D6 inhibitors (quinidine, fluoxetine, paroxetine, propafenone)Shown to double metoprolol concentrations and reduce cardioselectivity; monitor closely.DailyMed (U.S. NLM)
• Digitalis, clonidine, diltiazem, verapamil, fingolimodAdditive heart-rate lowering; when stopping clonidine, withdraw metoprolol several days earlier.DailyMed (U.S. NLM)

• Published observational studies have not shown an association between maternal metoprolol use and adverse developmental outcomes; untreated hypertension and heart failure carry maternal and fetal risks.International label, same formulation · DailyMed (U.S. NLM)
• Present in human milk; relative infant dose about 0.5-2% of the maternal weight-adjusted dose; if the mother is a slow metabolizer, monitor the infant for bradycardia and other beta-blockade signs.International label, same formulation · DailyMed (U.S. NLM)

• Metoprolol tartrate: Competitively blocks beta1-adrenergic receptors in the heart, lowering heart rate, contractility and blood pressure; cardioselectivity diminishes at higher plasma concentrations.